Zymergen raised $883 million across major rounds, including a $300M Series D in 2020 backed by Baillie Gifford, DCVC, and SoftBank Vision Fund. Its earlier $406M Series C in 2018 also included investors like Two Sigma Ventures, DFJ, and Goldman Sachs Investment Partners. Zymergen’s Series B, totaling $130M, came from DCVC, SoftBank Capital, and Iconiq Capital, propelling the company to unicorn status within six years. With a strong investor base and advanced bio-manufacturing capabilities, Zymergen became one of the most heavily funded synthetic biology players prior to its acquisition.